22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Aralez sales and marketing update

Aralez launched once-daily Yosprala 325/40 ( PA32540 ) and Yosprala 81/40 ( PA8140 ) in the U.S. for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The products are...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Aralez deal

AstraZeneca granted Aralez’s Aralez Pharmaceuticals Trading DAC subsidiary exclusive, U.S. rights to market branded and authorized generic Toprol-XL metoprolol. AZ will receive $175 million up front and is eligible for up to $48 million in...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Yosprala 325/40 regulatory update

FDA approved an NDA from Aralez for Yosprala 325/40 (PA32540) and Yosprala 81/40 ( PA8140 ) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Aralez plans to launch...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Yosprala 81/40 regulatory update

FDA approved an NDA from Aralez for Yosprala 325/40 ( PA32540 ) and Yosprala 81/40 (PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Aralez plans to launch...
07:00 , Sep 15, 2016 |  BC Extra  |  Company News

FDA approves Aralez's Yosprala

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ; TSX:ARZ) said FDA approved an NDA for Yosprala 325/40 ( PA32540 ) and Yosprala 81/40 ( PA8140 ) to prevent cardiovascular and cerebrovascular events in patients who require aspirin and are...